IPAX-1 Study of TLX101 Investigational Therapy for Glioblastoma Published in Neuro-Oncology Advances Page 1

MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in
Advances in neuro-oncology, confirmation of the safety and tolerability profile and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain tumor.

TLX101 (4-L-( ¹³¹I) iodo-phenylalanine, or ¹³¹I-IPA) is a systemically administered, targeted radiotherapy that targets L-type amino acid transporter 1 (LAT1), which is typically overexpressed in GBM.